You are here
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Harriet Kluger, Margaret K. Callahan, Michael A. Postow, Naiyer A. Rizvi, Alexander M. Lesokhin, Neil H. Segal, M.D., Ph.D., Charlotte E. Ariyan, M.D., Ph.D., Ruth-Ann Gordon, Kathleen Reed, Matthew M. Burke, Anne Caldwell, Stephanie A. K
N Engl J Med 2013; 369:122-133 July 11, 2013
The use of the antibody Ipilimumab, which interferes with one important checkpoint during immune activation can induce some clinical responses and has an impact on longterm survival of patients with metastatic melanoma. Now antibodies interfering with another immune checkpoint, the PD1-molecule present on activated T-cells, are documented to result in a significant number of rapid and stable remissions. These two papers announce a new era in immunotherapy that will have an impact on the management of advanced cancer patients of several types, including lung cancer and renal cell carcinoma.
Concurrent therapy with nivolumab and ipilimumab had a manageable safety profile and provided clinical activity that appears to be distinct from that in published data on monotherapy, with rapid and deep tumor regression in a substantial proportion of patients.